BioBusiness

Knowing where key biomanufacturing facilities are located around the world is essential for decision-making.

Those who doubt there's faith in science, should check out our annual Bioprocessing Survey.

Two films portray, in surprising detail, the hard work and determination of the biopharmaceutical industry.

Research and development headed for divorce.

Industry starts the year with a positive spin.

Those at the top must walk the walk of uncompromising commitment to compliance

How did biopharmaceutical professionals fare during a year of hiring freezes, high anxiety, and increased workload? Our survey finds out.

Why this workforce trend is well-suited for pharmaceutical companies.

Business models that were used to create current value are no longer going to be effective going forward.

To achieve manufacturing excellence, biopharma companies must adopt four key operating principles.

Managing partnerships for the greater good.

Biotech approvals were up last year. Is it a sign of a new trend?

Biotech's mid-sized elites position themselves for growth.

An in-depth analysis of the patent provisions of the new legislation.

In light of the new ruling, patent licensees may want to re-evaluate the strength of their licensed patents.

After a bright start to the year, some of biotech's blue chip companies have seen their early gains turn into losses.

Thomson Reuters' Mark Gordon looks at how real partnership opportunities are developing in a virtual pharma world.

Combine cost analyses with QbD to improve operations and lower costs.

The industry must be prepared for the impact of the sweeping changes expected from the new legislation.

As the capital markets in the US and globally continue to strengthen, the biotech industry can expect to see a rise in initial public offerings this year.

This year's BIO International Convention will be occurring against a backdrop of profound change in our industry.

The companies that have survived the financial meltdown are well placed to adapt to the new environment that we now are entering.

The year 2009 was marked by recession, industry megamergers, and venture-capital scarcity. How did biopharmaceutical professionals fare?

Gaining a license can be a complex process, but a few key tips can help you avoid common pitfalls and patent infringements.

A case study compares capital costs, operating expenses, and NPV for a new MAb plant.